Home / Research library / Sermorelin
Compound guide
Sermorelin: what the research covers
The first twenty-nine residues of growth hormone-releasing hormone, which turned out to be the shortest sequence that still activates the receptor. Everything else in the GHRH class is a response to what sermorelin cannot do.
What Sermorelin is
Native growth hormone-releasing hormone is forty-four amino acids long. Sermorelin is the first twenty-nine of them, and the discovery that made it interesting is that those twenty-nine carry essentially all of the biological activity: the remaining fifteen residues contribute to stability and clearance rather than to receptor engagement. The compound is therefore often written GRF(1-29).
It acts on the GHRH receptor expressed on pituitary somatotroph cells, a class-B G-protein-coupled receptor signalling through Gs, adenylate cyclase and cyclic AMP. The result is transcription and release of growth hormone from the cells that already make it.
The limitation is at position two. Alanine there is the preferred substrate of dipeptidyl peptidase-4, which cleaves the first two residues and destroys activity. Circulating half-life is measured in minutes. Every later analogue in this class — the substituted CJC-1295 series, the acylated tesamorelin — is an answer to that single vulnerability.
Why a short half-life is sometimes the point
Rapid clearance reads like a defect, and for a therapeutic it is. For an experiment it is often the feature. Exposure tracks the administration profile closely rather than smearing into a plateau, so an investigator who wants to study a defined pulse of GHRH signalling and then its absence has a cleaner tool in sermorelin than in a long-acting analogue.
The second experimental property is that sermorelin works through the pituitary rather than around it. Negative feedback from somatostatin and from circulating IGF-1 stays intact, so the system retains its own ceiling. That makes sermorelin a probe of pituitary responsiveness — is the gland capable of responding, and how much — in a way that exogenous somatropin cannot be, because somatropin bypasses the gland entirely.
Compared against a ghrelin receptor agonist such as ipamorelin, sermorelin engages a different receptor on the same cell. The two pathways are synergistic in published work, which is why combination designs appear so often in the literature.
How Amino Club supplies it
Sermorelin is supplied lyophilised in sealed vials as Sermorelin. Each batch is specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry, and released against the Certificate of Analysis carrying the batch number printed on the vial label. The lab testing page documents that sequence.
Because the molecule is a truncation rather than a substitution, mass spectrometry is the check that matters: a preparation short by one or two residues at either end would look similar on a purity trace while behaving quite differently. Sealed vials tolerate ambient transit and are stored below −18 °C long term; solvents are under reconstitution supplies.
Related reading
Sermorelin sits in the growth hormone research peptides group with CJC-1295, tesamorelin, ipamorelin, MK-677 and IGF-1 LR3. The comparison CJC-1295 with versus without DAC covers the half-life question in more detail.
The research library indexes every guide here. Certificates and storage are on the FAQ; quantity pricing through bulk and wholesale.
Research use only
Sermorelin supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.